These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29632023)

  • 1. Eltrombopag mobilizes iron in patients with aplastic anemia.
    Zhao Z; Sun Q; Sokoll LJ; Streiff M; Cheng Z; Grasmeder S; Townsley DM; Young NS; Dunbar CE; Winkler T
    Blood; 2018 May; 131(21):2399-2402. PubMed ID: 29632023
    [No Abstract]   [Full Text] [Related]  

  • 2. Eltrombopag combined with cyclosporine may have an effect on very severe aplastic anemia.
    Cheng H; Wang X; Zhou D; Cao J; Larochelle A; Xu KL
    Ann Hematol; 2019 Aug; 98(8):2009-2011. PubMed ID: 30891613
    [No Abstract]   [Full Text] [Related]  

  • 3. The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia.
    Gill H; Leung GM; Lopes D; Kwong YL
    Br J Haematol; 2017 Mar; 176(6):991-994. PubMed ID: 27097929
    [No Abstract]   [Full Text] [Related]  

  • 4. Eltrombopag in refractory aplastic anemia.
    Akard L
    N Engl J Med; 2012 Sep; 367(12):1162-3; author reply 1163. PubMed ID: 22992085
    [No Abstract]   [Full Text] [Related]  

  • 5. Eltrombopag in refractory aplastic anemia.
    Oshima Y; Yuji K; Tojo A
    N Engl J Med; 2012 Sep; 367(12):1162; author reply 1163. PubMed ID: 22992084
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag.
    Fattizzo B; Kulasekararaj AG; Hill A; Benson-Quarm N; Griffin M; Munir T; Arnold L; Riley K; Ireland R; De Lavallade H; Potter V; Consonni D; Hillmen P; Mufti GJ; Barcellini W; Marsh JCW
    Haematologica; 2019 Nov; 104(11):e494-e496. PubMed ID: 30890599
    [No Abstract]   [Full Text] [Related]  

  • 7. [Eltrombopag combined with cyclosporine alone for treatment of very severe aplastic anemia: a case report].
    Cheng H; Wang X; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):612. PubMed ID: 32397030
    [No Abstract]   [Full Text] [Related]  

  • 8. Eltrombopag for the treatment of aplastic anemia: current perspectives.
    Lum SH; Grainger JD
    Drug Des Devel Ther; 2016; 10():2833-2843. PubMed ID: 27695288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia.
    Filippidou M; Avgerinou G; Tsipou H; Tourkantoni N; Katsibardi K; Vlachou A; Roka K; Solomou E; Kattamis A
    Br J Haematol; 2020 Aug; 190(3):e157-e159. PubMed ID: 32529633
    [No Abstract]   [Full Text] [Related]  

  • 10. Eltrombopag: a stem cell cookie?
    Marsh JC; Mufti GJ
    Blood; 2014 Mar; 123(12):1774-5. PubMed ID: 24652959
    [No Abstract]   [Full Text] [Related]  

  • 11. Upfront eltrombopag monotherapy induces stable hematologic remission in pediatric patients with nonsevere idiopathic aplastic anemia.
    Geng W; Kearney S; Nelson S
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27290. PubMed ID: 29932285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis.
    Hong Y; Li X; Wan B; Li N; Chen Y
    Clin Drug Investig; 2019 Feb; 39(2):141-156. PubMed ID: 30406906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.
    Lengline E; Drenou B; Peterlin P; Tournilhac O; Abraham J; Berceanu A; Dupriez B; Guillerm G; Raffoux E; de Fontbrune FS; Ades L; Balsat M; Chaoui D; Coppo P; Corm S; Leblanc T; Maillard N; Terriou L; Socié G; de Latour RP
    Haematologica; 2018 Feb; 103(2):212-220. PubMed ID: 29170252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Safety and efficacy of the use of eltrombopag in a case of severe acquired bone marrow aplasia].
    Rubio-San-Simón A; Lázaro Rodríguez I; Vázquez Gómez F; Vivanco Martínez JL; Pérez Alonso V
    An Pediatr (Engl Ed); 2019 Apr; 90(4):246-247. PubMed ID: 29798814
    [No Abstract]   [Full Text] [Related]  

  • 15. A promising new treatment for refractory aplastic anemia.
    Metcalf D
    N Engl J Med; 2012 Jul; 367(1):74-5. PubMed ID: 22762322
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of eltrombopag in severe aplastic anemia treatment in children.
    Su MY; Chang HH; Chou SW; Lu MY; Yang YL; Lin DT; Lin KH; Jou ST
    Pediatr Neonatol; 2021 Nov; 62(6):655-657. PubMed ID: 34420905
    [No Abstract]   [Full Text] [Related]  

  • 17. Eltrombopag: a review of its use in patients with severe aplastic anaemia.
    McCormack PL
    Drugs; 2015 Apr; 75(5):525-31. PubMed ID: 25700916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eltrombopag in aplastic anemia.
    Desmond R; Townsley DM; Dunbar C; Young NS
    Semin Hematol; 2015 Jan; 52(1):31-7. PubMed ID: 25578417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eltrombopag for treatment of thrombocytopenia-associated disorders.
    Merli P; Strocchio L; Vinti L; Palumbo G; Locatelli F
    Expert Opin Pharmacother; 2015; 16(14):2243-56. PubMed ID: 26364898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
    Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
    N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.